Recombinant TCP1 alpha/CCTA antibody (full length)

Catalog No. ABIN7879126

The Rabbit Monoclonal anti-TCP1 alpha/CCTA antibody (Clone TP63-1423R) (ABIN7879126) specifically detects TCP1 alpha/CCTA in IHC (p). The antibody is reactive with Human, Mouse and Rat samples.

Quick Overview for Recombinant TCP1 alpha/CCTA antibody (full length) (ABIN7879126)

Target: TCP1 alpha/CCTA (TCP1) (T-Complex 1 (TCP1))

Antibody Type: Recombinant Antibody

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Monoclonal

Conjugate: This TCP1 alpha/CCTA antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: TP63-1423R

Product Details anti-TCP1 alpha/CCTA Antibody

Binding Specificity: full length

Purpose: Recombinant p63 Antibody / Rabbit Monoclonal

Purification: Protein A affinity chromatography

Immunogen: Full-length human recombinant protein was used as the immunogen for the recombinant p63 antibody.

Isotype: IgG, kappa

Application Details

Application Notes: Optimal dilution of the recombinant p63 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store the recombinant p63 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Target Details for TCP1 alpha/CCTA

Target: TCP1 alpha/CCTA (TCP1) (T-Complex 1 (TCP1))

Alternative Name: p63

Background: P63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands, however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90 % . Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80 %. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.

UniProt: Q9H3D4